Abstract
Asthma remains a formidable public health problem with ever increasing annual costs and prevalence. There are 300 million people with asthma worldwide. Per the Centers for Disease Control and Prevention, there are over 25 million Americans with asthma (both children and adults), i.e. one in 12 people have asthma, and this is increasing annually. Asthma results in approximately half a million hospitalizations and two million emergency department (ED) visits per year. In 2007 alone, 185 children and 3262 adults died from asthma, i.e. nine to ten patients die a day from asthma. This resulted in an annual cost of $56 billion in medical costs, lost work/school days, and early deaths. Therefore, we need novel and innovative therapies for asthma. In this Editorial, I review results from a study by Tse et al. evaluating the therapeutic potential of statins, within the context of our current state of knowledge. I review observational studies and clinical trials, highlight some potential pitfalls in clinical trial design, and discuss important questions for future research.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1051-1054 |
| Number of pages | 4 |
| Journal | Current Medical Research and Opinion |
| Volume | 30 |
| Issue number | 6 |
| DOIs | |
| State | Published - 2014 |
Fingerprint
Keywords
- Asthma
- Exacerbation
- Inhaled corticosteroids
- Statin
- Statins
ASJC Scopus subject areas
- Medicine(all)
Cite this
Statins and asthma : Where we stand, and the next critical steps in research. / Zeki, Amir.
In: Current Medical Research and Opinion, Vol. 30, No. 6, 2014, p. 1051-1054.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Statins and asthma
T2 - Where we stand, and the next critical steps in research
AU - Zeki, Amir
PY - 2014
Y1 - 2014
N2 - Asthma remains a formidable public health problem with ever increasing annual costs and prevalence. There are 300 million people with asthma worldwide. Per the Centers for Disease Control and Prevention, there are over 25 million Americans with asthma (both children and adults), i.e. one in 12 people have asthma, and this is increasing annually. Asthma results in approximately half a million hospitalizations and two million emergency department (ED) visits per year. In 2007 alone, 185 children and 3262 adults died from asthma, i.e. nine to ten patients die a day from asthma. This resulted in an annual cost of $56 billion in medical costs, lost work/school days, and early deaths. Therefore, we need novel and innovative therapies for asthma. In this Editorial, I review results from a study by Tse et al. evaluating the therapeutic potential of statins, within the context of our current state of knowledge. I review observational studies and clinical trials, highlight some potential pitfalls in clinical trial design, and discuss important questions for future research.
AB - Asthma remains a formidable public health problem with ever increasing annual costs and prevalence. There are 300 million people with asthma worldwide. Per the Centers for Disease Control and Prevention, there are over 25 million Americans with asthma (both children and adults), i.e. one in 12 people have asthma, and this is increasing annually. Asthma results in approximately half a million hospitalizations and two million emergency department (ED) visits per year. In 2007 alone, 185 children and 3262 adults died from asthma, i.e. nine to ten patients die a day from asthma. This resulted in an annual cost of $56 billion in medical costs, lost work/school days, and early deaths. Therefore, we need novel and innovative therapies for asthma. In this Editorial, I review results from a study by Tse et al. evaluating the therapeutic potential of statins, within the context of our current state of knowledge. I review observational studies and clinical trials, highlight some potential pitfalls in clinical trial design, and discuss important questions for future research.
KW - Asthma
KW - Exacerbation
KW - Inhaled corticosteroids
KW - Statin
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=84900823006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84900823006&partnerID=8YFLogxK
U2 - 10.1185/03007995.2014.881794
DO - 10.1185/03007995.2014.881794
M3 - Article
C2 - 24450485
AN - SCOPUS:84900823006
VL - 30
SP - 1051
EP - 1054
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
SN - 0300-7995
IS - 6
ER -